Nxstage Medical Inc (NXTM) 22.87 $NXTM
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:27AM CDT
Illumina (ILMN) faces high expenses related to the development of new products, their launch in various markets and investments in partnerships
ICUI: 115.74 (+0.74), NXTM: 22.87 (-0.04), GWPH: 96.35 (+1.52), ILMN: 139.64 (-1.61)
Halyard Health Now a Strong Buy, Portfolio Key Catalyst
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 7:54AM CDT
On Jul 8, 2016, Zacks Investment Research upgraded Halyard Health Inc (HYH) to a Zacks Rank #1 (Strong Buy).
HYH: 34.26 (-0.21), DSCI: 4.19 (-0.03), ICUI: 115.74 (+0.74), NXTM: 22.87 (-0.04)
NxStage® to Report Second Quarter 2016 Financial Results
PR Newswire - Fri Jul 01, 7:30AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the second quarter ended June 30, 2016, on Thursday, August 4, 2016, before the opening of the financial markets.
NXTM: 22.87 (-0.04)
Upgrade Alert for NxStage Medical (NXTM)
Comtex SmarTrend(R) - Wed Jun 29, 3:29AM CDT
NxStage Medical (NASDAQ:NXTM) was upgraded from Market Perform to Outperform at Northland today. The stock closed yesterday at $20.70 on volume of 1.8 million shares, above average daily volume of 452,000. There is potential upside of 17.6% for shares of NxStage Medical based on a current price of $20.70 and an average consensus analyst price target of $24.33. NxStage Medical shares have support at the 200-day moving average (MA) of $17.15 and additional support at the 50-day MA of $15.27.
NXTM: 22.87 (-0.04)
Why Investors Love These Medical Appliances & Equipment's Stocks? - Align Technology, ZELTIQ Aesthetics, Amedica, and Nxstage Medical
PR Newswire - Wed Jun 22, 6:45AM CDT
Growth is expected for the U.S. Medical Appliances and Equipment industry as demand for healthcare continues to rise. In today's pre-market research, Stock-Callers.com shifts its attention on these four equities for investors' close review: Align Technology Inc. (NASDAQ: ALGN), ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Amedica Corp. (NASDAQ: AMDA), and Nxstage Medical Inc. (NASDAQ: NXTM). Learn more about these stocks and receive your complimentary trade alerts at:
NXTM: 22.87 (-0.04), ZLTQ: 29.86 (+0.52), ALGN: 83.37 (+0.44), AMDA: 0.88 (unch)
Uptrend Call Working As NxStage Medical Stock Rises 33.4% (NXTM)
Comtex SmarTrend(R) - Fri Jun 10, 1:01PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 33.38% as of today's recent price of $20.82.
NXTM: 22.87 (-0.04)
Nxstage Medical (NXTM) Catches Eye: Stock Jumps 5.6%
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:40AM CDT
Nxstage Medical, Inc. (NXTM) saw its shares almost 6% in the last trading session.
NXTM: 22.87 (-0.04), BAX: 46.49 (-0.16)
Uptrend Call Working As NxStage Medical Stock Rises 25.8% (NXTM)
Comtex SmarTrend(R) - Fri Jun 03, 1:20AM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 25.82% as of today's recent price of $19.64.
NXTM: 22.87 (-0.04)
NxStage Medical Has Returned 19.2% Since SmarTrend Recommendation (NXTM)
Comtex SmarTrend(R) - Thu May 26, 1:52PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 19.15% as of today's recent price of $18.60.
NXTM: 22.87 (-0.04)
NxStage Announces Second Quarter 2016 Investor Conference Schedule
PR Newswire - Tue May 24, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to participate in the following schedule of investor conferences. Where applicable, a webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 22.87 (-0.04)
NxStage Medical Cuts Its Losses as Critical Care Leads Sales Higher
Dan Caplinger, The Motley Fool - Motley Fool - Wed May 04, 10:44AM CDT
Image source: NxStage Medical. Profitability often eludes small companies seeking to expand their businesses, and for home dialysis specialist NxStage Medical , the challenge of spending money on research and development while also marketing its...
NXTM: 22.87 (-0.04)
NxStage Reports First Quarter Financial Results
PR Newswire - Wed May 04, 7:05AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported first quarter financial results above the top end of its guidance.
NXTM: 22.87 (-0.04)
NxStage to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Mon Apr 25, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to present at the Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, 2016 at 8:40 a.m. ET in Boston, MA. A webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 22.87 (-0.04)
Zerto Launches the Inaugural ZertoCON: The Next Generation Business Continuity Conference
PR Newswire - Wed Apr 13, 7:30AM CDT
Zerto, setting the standard for protection, recovery and migration of data in cloud and virtualized data centers, today announced the launch of ZertoCON, the next generation business continuity conference, taking place May 23-25, 2016 in Boston, MA. Executives, thought leaders and IT professionals from a wide range of industries and organizations - including Zerto's management and product leaders - will focus on building confidence in IT to move businesses forward.
NXTM: 22.87 (-0.04)
NxStage® to Report First Quarter 2016 Financial Results
PR Newswire - Mon Apr 11, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the first quarter ended March 31, 2016, on Wednesday, May 4, 2016, before the opening of the financial markets.
NXTM: 22.87 (-0.04)
National Donate Life Month: NxStage Teams Up with Organ Donation Nonprofit MatchingDonors.com
PR Newswire - Thu Apr 07, 7:00AM CDT
Thirteen people die every day in the United States waiting for a kidney transplant, most waiting seven to nine years, according to the U.S. Department of Health and Human Services. April is National Donate Life Month and NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, is joining forces with MatchingDonors.com, the nation's largest nonprofit living organ donation website that provides people with an active way to search for an altruistic live donor. The organizations are teaming up to raise awareness of treatment options and services that may help kidney patients receive a transplant.
NXTM: 22.87 (-0.04)
NxStage Medical Has Returned 23.3% Since SmarTrend Recommendation (NXTM)
Comtex SmarTrend(R) - Thu Mar 03, 6:49PM CST
SmarTrend identified a Downtrend for NxStage Medical (NASDAQ:NXTM) on January 11th, 2016 at $20.11. In approximately 2 months, NxStage Medical has returned 23.25% as of today's recent price of $15.43.
NXTM: 22.87 (-0.04)
Why NxStage Medical, Inc. Guided Lower Today
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 10, 3:48PM CST
What: NxStage Medical is down 14% near the closing bell after releasing disappointing guidance during its fourth-quarter earnings release this morning. So what: Fourth-quarter revenue was pretty strong, up 12% year over year. NxStage Medical...
NXTM: 22.87 (-0.04)
NxStage Reports Record Fourth Quarter and Full-Year 2015 Revenue
PR Newswire - Wed Feb 10, 7:02AM CST
Highlights:
NXTM: 22.87 (-0.04)
NxStage® to Report Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Tue Jan 19, 7:00AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2015, on Wednesday, February 10, 2016, before the opening of the financial markets.
NXTM: 22.87 (-0.04)
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:27AM CDT
Illumina (ILMN) faces high expenses related to the development of new products, their launch in various markets and investments in partnerships
ICUI: 115.74 (+0.74), NXTM: 22.87 (-0.04), GWPH: 96.35 (+1.52), ILMN: 139.64 (-1.61)
Halyard Health Now a Strong Buy, Portfolio Key Catalyst
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 7:54AM CDT
On Jul 8, 2016, Zacks Investment Research upgraded Halyard Health Inc (HYH) to a Zacks Rank #1 (Strong Buy).
HYH: 34.26 (-0.21), DSCI: 4.19 (-0.03), ICUI: 115.74 (+0.74), NXTM: 22.87 (-0.04)
NxStage® to Report Second Quarter 2016 Financial Results
PR Newswire - Fri Jul 01, 7:30AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the second quarter ended June 30, 2016, on Thursday, August 4, 2016, before the opening of the financial markets.
NXTM: 22.87 (-0.04)
Upgrade Alert for NxStage Medical (NXTM)
Comtex SmarTrend(R) - Wed Jun 29, 3:29AM CDT
NxStage Medical (NASDAQ:NXTM) was upgraded from Market Perform to Outperform at Northland today. The stock closed yesterday at $20.70 on volume of 1.8 million shares, above average daily volume of 452,000. There is potential upside of 17.6% for shares of NxStage Medical based on a current price of $20.70 and an average consensus analyst price target of $24.33. NxStage Medical shares have support at the 200-day moving average (MA) of $17.15 and additional support at the 50-day MA of $15.27.
NXTM: 22.87 (-0.04)
Why Investors Love These Medical Appliances & Equipment's Stocks? - Align Technology, ZELTIQ Aesthetics, Amedica, and Nxstage Medical
PR Newswire - Wed Jun 22, 6:45AM CDT
Growth is expected for the U.S. Medical Appliances and Equipment industry as demand for healthcare continues to rise. In today's pre-market research, Stock-Callers.com shifts its attention on these four equities for investors' close review: Align Technology Inc. (NASDAQ: ALGN), ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Amedica Corp. (NASDAQ: AMDA), and Nxstage Medical Inc. (NASDAQ: NXTM). Learn more about these stocks and receive your complimentary trade alerts at:
NXTM: 22.87 (-0.04), ZLTQ: 29.86 (+0.52), ALGN: 83.37 (+0.44), AMDA: 0.88 (unch)
Uptrend Call Working As NxStage Medical Stock Rises 33.4% (NXTM)
Comtex SmarTrend(R) - Fri Jun 10, 1:01PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 33.38% as of today's recent price of $20.82.
NXTM: 22.87 (-0.04)
Nxstage Medical (NXTM) Catches Eye: Stock Jumps 5.6%
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:40AM CDT
Nxstage Medical, Inc. (NXTM) saw its shares almost 6% in the last trading session.
NXTM: 22.87 (-0.04), BAX: 46.49 (-0.16)
Uptrend Call Working As NxStage Medical Stock Rises 25.8% (NXTM)
Comtex SmarTrend(R) - Fri Jun 03, 1:20AM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 25.82% as of today's recent price of $19.64.
NXTM: 22.87 (-0.04)
NxStage Medical Has Returned 19.2% Since SmarTrend Recommendation (NXTM)
Comtex SmarTrend(R) - Thu May 26, 1:52PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 19.15% as of today's recent price of $18.60.
NXTM: 22.87 (-0.04)
NxStage Announces Second Quarter 2016 Investor Conference Schedule
PR Newswire - Tue May 24, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to participate in the following schedule of investor conferences. Where applicable, a webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 22.87 (-0.04)
NxStage Medical Cuts Its Losses as Critical Care Leads Sales Higher
Dan Caplinger, The Motley Fool - Motley Fool - Wed May 04, 10:44AM CDT
Image source: NxStage Medical. Profitability often eludes small companies seeking to expand their businesses, and for home dialysis specialist NxStage Medical , the challenge of spending money on research and development while also marketing its...
NXTM: 22.87 (-0.04)
NxStage Reports First Quarter Financial Results
PR Newswire - Wed May 04, 7:05AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported first quarter financial results above the top end of its guidance.
NXTM: 22.87 (-0.04)
NxStage to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Mon Apr 25, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to present at the Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, 2016 at 8:40 a.m. ET in Boston, MA. A webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 22.87 (-0.04)
Zerto Launches the Inaugural ZertoCON: The Next Generation Business Continuity Conference
PR Newswire - Wed Apr 13, 7:30AM CDT
Zerto, setting the standard for protection, recovery and migration of data in cloud and virtualized data centers, today announced the launch of ZertoCON, the next generation business continuity conference, taking place May 23-25, 2016 in Boston, MA. Executives, thought leaders and IT professionals from a wide range of industries and organizations - including Zerto's management and product leaders - will focus on building confidence in IT to move businesses forward.
NXTM: 22.87 (-0.04)
NxStage® to Report First Quarter 2016 Financial Results
PR Newswire - Mon Apr 11, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the first quarter ended March 31, 2016, on Wednesday, May 4, 2016, before the opening of the financial markets.
NXTM: 22.87 (-0.04)
National Donate Life Month: NxStage Teams Up with Organ Donation Nonprofit MatchingDonors.com
PR Newswire - Thu Apr 07, 7:00AM CDT
Thirteen people die every day in the United States waiting for a kidney transplant, most waiting seven to nine years, according to the U.S. Department of Health and Human Services. April is National Donate Life Month and NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, is joining forces with MatchingDonors.com, the nation's largest nonprofit living organ donation website that provides people with an active way to search for an altruistic live donor. The organizations are teaming up to raise awareness of treatment options and services that may help kidney patients receive a transplant.
NXTM: 22.87 (-0.04)
NxStage Medical Has Returned 23.3% Since SmarTrend Recommendation (NXTM)
Comtex SmarTrend(R) - Thu Mar 03, 6:49PM CST
SmarTrend identified a Downtrend for NxStage Medical (NASDAQ:NXTM) on January 11th, 2016 at $20.11. In approximately 2 months, NxStage Medical has returned 23.25% as of today's recent price of $15.43.
NXTM: 22.87 (-0.04)
Why NxStage Medical, Inc. Guided Lower Today
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 10, 3:48PM CST
What: NxStage Medical is down 14% near the closing bell after releasing disappointing guidance during its fourth-quarter earnings release this morning. So what: Fourth-quarter revenue was pretty strong, up 12% year over year. NxStage Medical...
NXTM: 22.87 (-0.04)
NxStage Reports Record Fourth Quarter and Full-Year 2015 Revenue
PR Newswire - Wed Feb 10, 7:02AM CST
Highlights:
NXTM: 22.87 (-0.04)
NxStage® to Report Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Tue Jan 19, 7:00AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2015, on Wednesday, February 10, 2016, before the opening of the financial markets.
NXTM: 22.87 (-0.04)
